USFDA Issues Warning To Glenmark On Ryaltris
  • WebDesk BTVI
  • Jun 24 2019

USFDA has issued a warning to Glenmark on Ryaltris. The letter which cites deficiencies in the drug master file pertaining to one API, however does not specify deficiencies with the clinical data. The company was planning to launch Ryaltris in October 2019, claiming to resolve this issue within the next 6-9 Months. BTVI's Abhishek Ranjan with more on this story.